{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:00:15Z","timestamp":1784563215496,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.neuint.2019.104543","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T02:12:25Z","timestamp":1567476745000},"page":"104543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Striatal overexpression of \u03b2-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats"],"prefix":"10.1016","volume":"131","author":[{"given":"Zeng-Rui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Ru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qian","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Shi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Long","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2019.104543_bib1","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/j.celrep.2016.11.050","article-title":"Downregulation of a GPCR by \u03b2-arrestin2-mediated switch from an endosomal to a TGN recycling pathway","volume":"17","author":"Abdullah","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuint.2019.104543_bib2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S1474-4422(15)00286-0","article-title":"Targeting pain in Parkinson's disease","volume":"14","author":"Antonini","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuint.2019.104543_bib3","doi-asserted-by":"crossref","first-page":"10265","DOI":"10.1523\/JNEUROSCI.23-32-10265.2003","article-title":"Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice","volume":"23","author":"Bohn","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2019.104543_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nbd.2015.10.020","article-title":"Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia","volume":"85","author":"Brugnoli","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2019.104543_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2710.2006.00714.x","article-title":"A potential novel strategy to separate therapeutic- and side-effects that are mediated via the same receptor: beta-arrestin2\/G-protein coupling antagonists","volume":"31","author":"Bruns","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.neuint.2019.104543_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/mds.27337","article-title":"Animal models of l-dopa-induced dyskinesia in Parkinson's disease","volume":"33","author":"Cenci","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2019.104543_bib7","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2019.104543_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biopsych.2014.04.002","article-title":"Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia","volume":"77","author":"Cerovic","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2019.104543_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","author":"Cotzias","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuint.2019.104543_bib10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1460-9568.2008.06040.x","article-title":"Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA","volume":"27","author":"Darmopil","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2019.104543_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cellsig.2016.02.013","article-title":"PSD-95 regulates CRFR1 localization, trafficking and \u03b2-arrestin2 recruitment","volume":"28","author":"Dunn","year":"2016","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuint.2019.104543_bib12","doi-asserted-by":"crossref","first-page":"21824","DOI":"10.1073\/pnas.1012071107","article-title":"Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia","volume":"107","author":"Fasano","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuint.2019.104543_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fnbeh.2011.00071","article-title":"L-DOPA-Induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission","volume":"5","author":"Feyder","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuint.2019.104543_bib14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.biopsych.2014.07.019","article-title":"A role for mitogen- and stress-activated kinase 1 in L-DOPA-induced dyskinesia and \u0394FosB expression","volume":"79","author":"Feyder","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.neuint.2019.104543_bib15","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1353-8020(13)70008-7","article-title":"Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse","volume":"20","author":"Francardo","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuint.2019.104543_bib16","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1523\/JNEUROSCI.22-12-05042.2002","article-title":"D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1\/2\/MAP kinase","volume":"22","author":"Gerfen","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2019.104543_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.parkreldis.2004.02.010","article-title":"DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia","volume":"10","author":"H\u00e5kansson","year":"2004","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuint.2019.104543_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.mce.2015.07.001","article-title":"Internalization and desensitization of the human glucose-dependent-insulinotropic receptor is affected by N-terminal acetylation of the agonist","volume":"414","author":"Ismail","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.neuint.2019.104543_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neulet.2004.02.068","article-title":"Striatal tyrosine hydroxylase immunoreactive neurons are induced by L-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats","volume":"362","author":"Jollivet","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuint.2019.104543_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nature17154","article-title":"The conformational signature of \u03b2-arrestin2 predicts its trafficking and signalling functions","volume":"531","author":"Lee","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuint.2019.104543_bib21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.molcel.2006.11.007","article-title":"New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors","volume":"24","author":"Lefkowitz","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neuint.2019.104543_bib22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1126\/science.2163110","article-title":"beta-Arrestin: a protein that regulates beta-adrenergic receptor function","volume":"248","author":"Lohse","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.neuint.2019.104543_bib23","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.2003.01632.x","article-title":"Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia","volume":"84","author":"Lundblad","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuint.2019.104543_bib24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/B978-0-12-394440-5.00018-8","article-title":"Arrestin pathways as drug targets","volume":"118","author":"Luttrell","year":"2013","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.neuint.2019.104543_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/pr.109.002436","article-title":"Beyond desensitization: physiological relevance of arrestin-dependent signaling","volume":"62","author":"Luttrell","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuint.2019.104543_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.26103","article-title":"Presynaptic effects of levodopa and their possible role in dyskinesia","volume":"30","author":"Mosharov","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2019.104543_bib27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14728222.2017.1279149","article-title":"Potential for targeting dopamine\/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders","volume":"21","author":"Nishi","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuint.2019.104543_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","article-title":"ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice","volume":"59","author":"Pav\u00f3n","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2019.104543_bib29","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","article-title":"Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia","volume":"27","author":"Santini","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2019.104543_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012322","article-title":"Distinct changes in cAMP and extracellular signal-regulated protein kinasesignalling in L-DOPA-induced dyskinesia","volume":"5","author":"Santini","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuint.2019.104543_bib31","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40263-014-0205-z","article-title":"Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease","volume":"28","author":"Schaeffer","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuint.2019.104543_bib32","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2019.104543_bib33","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1002\/mds.22052","article-title":"Treatment of levodopa-induced motor complications","volume":"23","author":"Stocchi","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2019.104543_bib34","doi-asserted-by":"crossref","first-page":"E2517","DOI":"10.1073\/pnas.1502740112","article-title":"Targeting \u03b2-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"112","author":"Urs","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuint.2019.104543_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1073\/pnas.0408305102","article-title":"Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum","volume":"102","author":"Valjent","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuint.2019.104543_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fnagi.2017.00331","article-title":"Levodopa\/benserazide loaded microspheres alleviate L-dopa induced dyskinesia through preventing the over-expression of D1R\/shp-2\/ERK1\/2 signaling pathway in a rat model of Parkinson's disease","volume":"9","author":"Wan","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuint.2019.104543_bib37","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1523\/JNEUROSCI.0195-15.2015","article-title":"Are striatal tyrosine hydroxylase interneurons dopaminergic?","volume":"35","author":"Xenias","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2019.104543_bib38","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1038\/srep07506","article-title":"Levodopa\/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1\/PKA\/P-tau pathway in 6-OHDA-lesioned Parkinson's rats","volume":"4","author":"Xie","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuint.2019.104543_bib39","doi-asserted-by":"crossref","first-page":"23527","DOI":"10.1038\/srep23527","article-title":"Inhibition of Glycogen Synthase Kinase-3\u03b2 (GSK-3\u03b2) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats","volume":"6","author":"Xie","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuint.2019.104543_bib40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jmb.2010.12.034","article-title":"Crystal structure of arrestin-3 reveals the basis of the difference in receptor binding between two non-visual subtypes","volume":"406","author":"Zhan","year":"2011","journal-title":"J. Mol. Biol."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018619303778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018619303778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:46:27Z","timestamp":1759311987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018619303778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"alternative-id":["S0197018619303778"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2019.104543","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Striatal overexpression of \u03b2-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2019.104543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104543"}}